# CooperCompanies Announces Release Date for Fourth Quarter and Full Year 2025
Canonical URL: https://biopharmsignal.com/news/COO/coopercompanies-announces-release-date-for-fourth-quarter-and-full-year-2025-7517ae1b
Ticker: COO
Company: The Cooper Companies
Source: The Cooper Companies
Published: 2025-11-04 21:15 EST
## Summary

CooperCompanies (Nasdaq: COO), a leading medical device company, announced today it will report...

## Article Body
CooperCompanies (Nasdaq: COO), a leading medical device company, announced today it will report fourth quarter and full year 2025 financial results on Thursday, December 4, 2025, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments.

The dial-in number for the call is 800-715-9871 and the conference ID is 2700541. A simultaneous audio webcast and subsequent replay can be accessed at http://investor.coopercos.com .

About CooperCompanies CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on helping people experience life’s beautiful moments through its two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, helping to improve the way people see each day. CooperSurgical is a leading fertility and women’s healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most. Headquartered in San Ramon, CA, CooperCompanies has a workforce of more than 16,000, sells products in over 130 countries, and positively impacts over fifty million lives each year. For more information, please visit www.coopercos.com .

Contact: Kim Duncan Vice President, Investor Relations and Risk Management 925-460-3663 ir@cooperco.com
## Recent Company News
- 2026-06-30 20:15 EST — [CooperCompanies Releases 2025 Corporate Sustainability Report with Scope 3 Emissions Disclosure](https://biopharmsignal.com/news/COO/coopercompanies-releases-2025-corporate-sustainability-report-with-scope-3-emiss-7902aa71) — Source: The Cooper Companies
- 2026-06-04 20:15 EST — [CooperCompanies Announces Second Quarter 2026 Results](https://biopharmsignal.com/news/COO/coopercompanies-announces-second-quarter-2026-results-b3a604de) — Source: The Cooper Companies
- 2026-05-04 20:15 EST — [CooperCompanies Appoints Paul Keel to its Board of Directors](https://biopharmsignal.com/news/COO/coopercompanies-appoints-paul-keel-to-its-board-of-directors-f12e0190) — Source: The Cooper Companies
- 2026-04-30 20:15 EST — [CooperCompanies Announces Release Date for Second Quarter 2026](https://biopharmsignal.com/news/COO/coopercompanies-announces-release-date-for-second-quarter-2026-d53e901c) — Source: The Cooper Companies
- 2026-03-05 21:15 EST — [CooperCompanies Announces First Quarter 2026 Results](https://biopharmsignal.com/news/COO/coopercompanies-announces-first-quarter-2026-results-c5617842) — Source: The Cooper Companies
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)